The Klerksdorp CRS is in the Dr Kenneth Kaunda District in the North West Province of South Africa, approximately 160km south-west, and a two-hour drive, from Johannesburg. The district with approximately 600,000 inhabitants, consists of four sub-districts of which the Matlosana Local Authority (and health sub-district) is the largest with 408,375 people of whom 360,200 are urban and 48,200 are rural.
About The Research Centre
Matlosana includes four adjacent towns with their previously racially segregated Black townships: Klerksdorp with its neighbouring township of Jouberton, Stillfontein with Khuma, Hartbeesfontein with Tigane and Orkney with Kanana. Klerksdorp/Jouberton is by far the largest town in Matlosana. Economic activity is predominantly mining of gold and associated industries. Although the contribution of gold mining is waning, there is still a substantial number of migrant mine workers in the area. There are two public sector hospitals in Matlosana administered as a single entity called the Klerksdorp Tshepong Hospital Complex (KTHC). The hospital complex is a regional referral facility, receiving patients for some specialities from the entire North West Province. It, in turn, refers patients for subspecialty care (eg cardiothoracic) to the teaching hospitals of the University of the Witwatersrand in Johannesburg. The Matlosana sub-district has 16 primary care clinics; four operate 24 hours per day.
The site has successfully eight HIV vaccine trials one Microbicide trial, two TB vaccine trial, and numerous observational studies.
The site has the capacity to enrol 300-500 participants over 12 months.
Population HIV prevalence in North West Province is estimated to be 13.9% (95%CI:12.0-16.1) and antenatal HIV seroprevalence surveys in pregnant women in the entire North West Province show that seroprevalence was 29.7% (95%CI:27.5-32.0). The same antenatal prevalence data for the Dr Kenneth Kaunda Health District suggests HIV seroprevalence was 36% (95%CI:31.9-41.3) in 2011 and 29.1%(95%CI:24.7-34.0) in 2012. Studies conducted at the CRS suggest a range of HIV incidence from 1.7-6.2 HIV infections per 100 person years of follow up depending on risk behaviour category.
Trials completed to date (721 participants):
- HIV Vaccine Phase I/IIa – 5 (HVTN/VIRAX – 210 enrolled)
- HIV Vaccine Phase IIb – 1 (HVTN – 221 enrolled)
- TB Vaccine Phase IIb – 1 (Aeras – 26 enrolled)
- HIV Prevention Phase IIb – 1 (MTN – 263 enrolled)
- TB Treatment Phase II – 1 (TIBOTEC – 1 enrolled)